Literature DB >> 31034392

Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.

Erika Mohr1, Gabriella Ferlazzo2, Cathy Hewison3, Virginia De Azevedo4, Petros Isaakidis5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31034392     DOI： 10.1016/S1473-3099(19)30168-9

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  4 in total

Review 1.  New Developments and Insights in the Improvement of Mycobacterium tuberculosis Vaccines and Diagnostics Within the End TB Strategy.

Authors:  Juan Ignacio García; Anna Allué-Guardia; Radhika P Tampi; Blanca I Restrepo; Jordi B Torrelles
Journal:  Curr Epidemiol Rep       Date:  2021-04-07

2.  Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline.

Authors:  Lénaïg Tanneau; Mats O Karlsson; Andreas H Diacon; Justin Shenje; Jorge De Los Rios; Lubbe Wiesner; Caryn M Upton; Kelly E Dooley; Gary Maartens; Elin M Svensson
Journal:  Clin Pharmacokinet       Date:  2022-06-07       Impact factor: 5.577

3.  Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens.

Authors:  Lénaïg Tanneau; Mats O Karlsson; Susan L Rosenkranz; Yoninah S Cramer; Justin Shenje; Caryn M Upton; Joel Morganroth; Andreas H Diacon; Gary Maartens; Kelly E Dooley; Elin M Svensson
Journal:  Clin Pharmacol Ther       Date:  2022-07-13       Impact factor: 6.903

4.  Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.

Authors:  Helena Huerga; Uzma Khan; Mathieu Bastard; Carole D Mitnick; Nathalie Lachenal; Palwasha Y Khan; Kwonjune J Seung; Nara Melikyan; Saman Ahmed; Michael L Rich; Francis Varaine; Elna Osso; Makhmujan Rashitov; Naseem Salahuddin; Gocha Salia; Epifanio Sánchez; Armine Serobyan; Muhammad Rafi Siddiqui; Dri Grium Tefera; Dmitry Vetushko; Lusine Yeghiazaryan; David Holtzman; Shirajul Islam; Andargachew Kumsa; Gamarly Jacques Leblanc; Olga Leonovich; Shahid Mamsa; Mohammad Manzur-Ul-Alam; Zaw Myint; Shrivani Padayachee; Molly F Franke; Catherine Hewison
Journal:  Clin Infect Dis       Date:  2022-10-12       Impact factor: 20.999
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.